

FOSUN PHARMA
复星医药

2023



1

2

3

4

5

6



414.00

(-5.81%YoY)

+ 12.43%YoY

mRNA

PD-1

HER2

(

)

59.37

(+ 0.88%YoY)

43.46

+1.02%YoY

34.14

(-19.05%YoY)

23.86

(-36.04%YoY)

6.83

2

1

Gland Pharma

20.11

(-48.08%YoY)

5.47

3.37

2.64

Cenexi

2023

2/2

2023	2022
414.00	439.52
198.05	207.82
47.8%	47.3%
97.12	91.71
23.5%	20.9%
24.4%	26.4%
43.75	38.28
10.6%	8.7%
43.46	43.02

2023

1/2




PD-1

2023 11.20 (+230.20%)
 3 ES-SCLC ES-SCLC PD-1
 9 ESCC
 12 ES-SCLC



Argesun

6 WHO PQ 21
 #
 2 P-CAB DU RE 2024 1 *
 #
 6 2024 1 *
 #
 5 CKD SHPT
 #
 8
 6 r/r LBCL
 #
 3 2021
 #
 3 2019



ES-SCLC
 ESCC
 P-CAB
 DU
 RE
 CKD

SHPT
 r/r LBCL
 MAA
 nsNSCLC
 BLA
 NF1 I

B

#

*

2023 9 30



® PD-1

3 ES-SCLC MAA EMA
 11 nsNSCLC NDA



HER2

2023 27.49 +58.19%YoY
 2 BLA FDA
 RT002 #
 1) 2
 4 7

Profhilo

#

11

Tenapanor

#

CKD

7

FCN-437c

CDK4/6

HR

HER2

11

FS-1502

HER2-ADC #

HER2

3

III

13

4

III

2

ET-26

10

III

FCN-159 MEK

1

2

4

7

/

NF1



GT1-GT6 Go/No Go

TRC Translational Research Center

SAB Scientific Advisory Board

8 FDA HER2

Pre-License Inspection

10 FDA

Pre-Approval Inspection

Gland Pharma 3 FDA GMP

10

GMP 12 GMP

GMP GMP

12 PD-1 ES-SCLC

4 CD20 16

Boston Oncology 8 PD-1 Kgbio

12 10 PD-1

Intas 4200

Sisram

Gland Pharma 4 Cenexi

12 Insightec

HER2 (PD-1)

2024 1 *

10

Xi 12

2024 3 Ion

*



HLX-10 (PD-1)
HLX-22 (HER-2)

ADC

FS-1502 (HER-2 ADC)
HLX-43 (PD-L1 ADC)
HLX-42 (EGFR ADC)

XS-02 (CHK1)
XS-03 (PLK1)
FCN-159 (MEK1/2)
FH2001 (FGFR/VEGFR)



(CD20)
HLX-15 (CD38)

FKC-876 (CD19-CAR-T)
FKC-889 (CD19-CAR-T)
GCK-01 (CAR-NK)

XS-04



VS-S103 (GLP1)

Tenapanor (ESRD-HD)
XH-S004



ET-26 (GABA)
Opicapone (COMT)



FKC-288
(CAR-T)
XH-S003 (Factor B)



13
24

2023年		 / ADC	
	 () (DU) (RE) )  (CKD)) SHPT )	 1 ES-SCLC 9 ESCC 12 Zerpidio	 r/r LBCL  Vero *
/	NDA/BLA ) FCN-437c(CDK4/6 2L)) Tenapanor() Opicapone() Pretomanid XDR MDR-TB III FCN-437c(CDK4/6 1L)) FCN-159(MEK1/2) SAF-189(ALK) ALK+ ET-26	NDA/BLA  NDA MAA EMA ) BLA FDA RT002 Prothilo III /  ES-SCLC FS-1502 HER2-ADC HER2 HLX04-O VEGF wAMD HLX11 HER2 HLX14 RANKL OP	III / 13 III  r/r iNHL FKC889 r/r MCL B r/r ALL
/	FCN-159(MEK1/2) / NF1 I 7 4	HLX208 BRAFV600E LCH Erdheim-Chester ECD HLX42 EGFR ADC EGFR EGFR	 r/r iNHL

*

2023 9 30



M SCI ESG
ESG

A
CSR

ESG



2023
+19%YoY

1.3
10,114
2,879,342
+110%YoY
100%

1,056
+7%YoY



Argesun
eCME
ESG

10
3.4
18
49.53%
4
8
WHO PQ
6,800
39.7%



ESG
ESG
ESG
ESG
ESG
ESG
ESG
ESG
ESG
ESG





3400+
70+


48,000L
100+
600+
9 FDA GMP



~5,000
~1,000



-



-

SCLC

PD-1



2023

11.20



PD-1

MSI-H

sqNSCLC

ES-SCLC

ESCC

ES-SCLC

SCLC FDA EC

ES-SCLC

ES-SCLC

MAA

EMA



ES-SCLC

III

(OS)

OS

15.4

10.9

24

43.1%

7.9%

JAMA

Nature Medicine

British Journal of Cancer



580

PD-1

8

PD-1

KGbio

12

10

PD-1

Intas

4,200

12

PD-1

ES-SCLC

PD-1

2023 6 r/r LBCL

CAR-T

2023

10

4

5 10

4

VERO

3 5

8


()

1 3

34



2023





1 P-CAB

III

8
95.8%
6
94.4%

*



PEG


10%

*



HFREF

20%
21%



NK-1

5-HT3

96h

CINV
96.6%

CINV
97.6%
86%



3~4

III 7

FGF23

(PTH)
23

RT-002

-

1)

4

7

FDA

9

2

6



ET-26

-

10

III

FS-1502

-

HER2

F

HER2

III

HER2

HER2

I

ORR 53.7%

67

PFS

15.5

HER2

/

II

HER2

FS-1502

13

PCV 13

2

6A
23F

6B

7F

9V

14

1

18C

3

19A

4

19F

5

4


III

Gland
Pharma







1



2,3



3



2022
2023

Sisram

Breas /

10

CT

2024 3 lon NMPA *

2023

Series

T

PCR-


F-A7000

- 1
 - 2
 - 3
- 1
- 2



Sisram
100

78%



/

Soprano Titanium



BeautiFill

Opus

FDA

LipoSense

CellFie



Ion

2024 3 Ion *

Ion

Ion


Ion





2023

6,548 * 8



2023 9 30




()

552,148



596,570



(



(

)




9,054




2,101





1			2019 2 2 RA	3 RA	1	
2			1 HER2 Phoenix S.A.	2 Accord Healthcare Limited	3 PT Kalbio Global Medika Laboratoro ELEA 40 Zercepac Tuzucip Trastucip	
3			PD-1 1 2023 CSCO CSCO	2022 3 MSI-H CSCO CSCO	2 CSCO 9 PD-1 3	
4			2020 12 1	2 GMP 3	4	
5		*	2020 4		ITP	

6		*	2021 8 PDE4	4	
7		*	2019 8 NK-1 5-HT3		
8		*	2023 6	1	
9		T *	SOT		
10			2021 6 1 12 B B CAR-T r/rDLBCL r/rLBCL	2	
11					

12		*	2023 5 SHPT	CKD	
13		*	P-CAB 2023 2 DU/RE P-CAB 1 DU RE	2024 3 26	
14			Artesun Artesun SPAQ-CO + D-ARTEPP 1 2023 12 33 WHOPQ Artesun 2023 6 WHOPQ 21 2023 12 3.4		
15		*	RNA 2022 7	HIV-1	
16		mRNA *	(mRNA BNT162b2) (/Omicron BA.4-5) XBB1.5 5 11 6 4	XBB1.5 Omicron	
17		Vero	Vero 2016 9 (Vero) CIN1v, 2024 3 (vero)	1.0ml 1 1.0ml	

18			0.5ml/ 2009 7 2005 11 0.25ml/ WHO 1 3	
19				
20		*	2023 8 (NYHAI-IV IVEF<40%)	

1/2

			/			IND	1	2	3	NDA
	HLX10 ¹	+	PD-1	/		III	2022	11		
						2022	FDA/EC	2023	1	
		+ +	PD-1		III	2023	1			
		+	PD-1+VEGF							
		+HLX07	PD-1+EGFR							
		+HLX07 +	PD-1+EGFR +VEGF							
	+HLX208 [#]	PD-1+BRAFV600E	BRAFV600E	BRAFV600E						
	HLX07		EGFR							
	HLX22 [#]	+	HER2							
		+ +	HER2+ PD-1 + HER2							
	HLX11		2	HER2		III				
	HLX05		3	EGFR						
	HLX02		4	HER2		FDA	2020			
FS-1502 [#]	-	HER2	HER2							
		HER2	HER2							
	+	PD-1	HER2							



				/			IND	1	2	3	NDA
	HLX26	+		LAG-3+PD-1	mCRC						
		+	+								
			-	LAG-3							
	HLX15			CD38		2023 2					
	HLX51			OX40							
	HLX13			CTLA-4							
	HLX53			TIGIT							
	HLX60	+	-	GARP							
				GARP+PD-1		I					
	HLX42			EGFR	/		FDA				
HLX43			PD-L1	/							
VT-101											
SurVaxM [#]			Survivin								
	(T)			-	GvHD						
				50R	INSR						
				25R	INSR						
				GLP-1							
				GLP-1		2024 I *					
				INSR							
HLX04-O ¹			VEGF		2022 2 III						
HLX14 2			RANKL		2022 6 III 2022 7 TGA III						
RT002 [#]				GL	2023 4						
				CD	2023 7						
GC101			COL7A1 CGT								

1/2

		/			IND	1	2	3	NDA
FCN-437c		CDK4/6	2L						
			1L						
SAF-189		ALK/ROS1	ALK+						
			ROS1+						
HLX208 [#]	-	BRAF	Erdheim-Chester ECD LCH		2023	4	LCH	ECD	NMPA
	+	BRAF+PD-1	BRAFV600E BRAFV600						
FCN-159		MEK1/2	I		2023	7	NMPA	II	
					2023	4	NMPA		
YP01001		VEGFR							
FCN-338	+	BCL-2							
	-			I					
	-		B	I					
FH-2001		FGFR/VEGFR							
XS-03		PLK1	RAS						

		I			IND	1	2	3	NDA
	#	TPO-R	ITP						
Tenapanor #		NHE3	CKD						
				2023 7 NDA NMPA					
Tenapanor #		NHE3	(IBS-C)		I				
Pretomanid #		-	XDR-TB / MDR-TB						
				Pretomanid*					
OP0595(Nacubactam) # +		-							
Opicapone #		COMT			Ongentys*				
Fortacin #		-			*				
ET-26		-							
				2023 10 III					
FCN-159		MEK1/2							
SZEY-2108		-	CRE						
				2023 6 NMPA					
XH-S002		FXIa							
FCN-016		ROCK							
				2023 1 NMPA					
XH-S003		Factor B	IgA		I	2024 3	I		

			IND	1	2	3	NDA



/

T



CHO



/ /


VERO

/

mRNA



-



	2023 1
8	ESG

1/2

4+7		5mg	3
		10mg	1
		250mg	3
		150mg	3
		2.5mg	3
		100mg	4
		40mg	2
		100mg	3
		1mg/2mg	3
		250mg	2
		10mg	3
		40mg	5
	2	10mg	4
	1	500mg	1
		200mg	2
		20mg	5
		250mg	1

1 1

6

2

3

4

5

2/2

	D	D	#	4
			50mg	4
			10ml/3ml	5
	(30/70)		3ml	6
			1g/0.25g/0.5g/2g	4
			0.25g/0.5g/1g	2
			5ml/10ml/20ml	2
			150mg	3

Fosun Pharma, the Representor or the P.000010733.68 20d4MCID 17/Lang (en-US)>BDC 0.000010729 0 720 405.12 reW* nBT/F2 9.96 Tf1 0 0 1495CID





www.fosunpharma.com